BioNexus Price To Free Cash Flows Ratio from 2010 to 2024
| BGLC Stock | USD 0.24 0.01 4.00% |
Price To Free Cash Flows Ratio | First Reported 2010-12-31 | Previous Quarter (5.80) | Current Value (5.51) | Quarterly Volatility 27.5 K |
Check BioNexus Gene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNexus Gene's main balance sheet or income statement drivers, such as Interest Expense of 7 K, Other Operating Expenses of 6.4 M or Net Income Applicable To Common Shares of 907.5 K, as well as many indicators such as Price To Sales Ratio of 0.82, Dividend Yield of 7.0E-4 or PTB Ratio of 0.91. BioNexus financial statements analysis is a perfect complement when working with BioNexus Gene Valuation or Volatility modules.
BioNexus | Price To Free Cash Flows Ratio |
Latest BioNexus Gene's Price To Free Cash Flows Ratio Growth Pattern
Below is the plot of the Price To Free Cash Flows Ratio of BioNexus Gene Lab over the last few years. It is BioNexus Gene's Price To Free Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNexus Gene's overall financial position and show how it may be relating to other accounts over time.
| Price To Free Cash Flows Ratio | 10 Years Trend |
|
Price To Free Cash Flows Ratio |
| Timeline |
BioNexus Price To Free Cash Flows Ratio Regression Statistics
| Arithmetic Mean | (12,872) | |
| Coefficient Of Variation | (213.94) | |
| Mean Deviation | 22,187 | |
| Median | (153.90) | |
| Standard Deviation | 27,538 | |
| Sample Variance | 758.3M | |
| Range | 97.5K | |
| R-Value | 0.74 | |
| Mean Square Error | 369.4M | |
| R-Squared | 0.55 | |
| Significance | 0 | |
| Slope | 4,557 | |
| Total Sum of Squares | 10.6B |
BioNexus Price To Free Cash Flows Ratio History
About BioNexus Gene Financial Statements
BioNexus Gene stakeholders use historical fundamental indicators, such as BioNexus Gene's Price To Free Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Although BioNexus Gene investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioNexus Gene's assets and liabilities are reflected in the revenues and expenses on BioNexus Gene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioNexus Gene Lab. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price To Free Cash Flows Ratio | (5.80) | (5.51) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:Check out the analysis of BioNexus Gene Correlation against competitors. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.06) | Revenue Per Share 0.526 | Quarterly Revenue Growth (0.23) | Return On Assets (0.10) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.